Major Advance in the Treatment of Axial Spondyloarthritis Coming Major Advance in the Treatment of Axial Spondyloarthritis Coming

Rheumatologists can look forward to the likely regulatory approval of the oral Janus kinase inhibitors tofacitinib and upadacitinib for the treatment of axial spondyloarthritis in the first half of 2021.Medscape Medical News

Source: Medscape Rheumatology Headlines - February 26, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news